Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
17 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Nezglyal“
Suchtreffer
Begriffe & Kennungen
Nezglyal · 4.8 Undesirable effects · 1
Eintrag öffnenNezglyal · 4.8 · 7 Tabulated list of adverse reactions
Eintrag öffnenNezglyal · 4.8 · 8 Reporting of suspected adverse reactions
Eintrag öffnenNezglyal · 4.8 · Adverse reactions in children (2 to 12 years of age) are listed in Table 4. Adverse reactions are classified a
Eintrag öffnenNezglyal · 4.8 · Anaemia Anaemia (including anaemia and iron deficiency anaemia) has been reported in patients from laboratory
Eintrag öffnenNezglyal · 4.8 · Description of selected adverse reactions
Eintrag öffnenNezglyal · 4.8 · In children (2 to 12 years of age), the most commonly reported adverse reactions during leriglitazone treatmen
Eintrag öffnenNezglyal · 4.8 · Oedema and eyelid oedema Oedema (including oedema and eyelid oedema) have been reported in patients treated wi
Eintrag öffnenNezglyal · 4.8 · Paediatric population
Eintrag öffnenNezglyal · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenNezglyal · 4.8 · Summary of the safety profile
Eintrag öffnenNezglyal · 4.8 · System organ class Adverse reaction Frequency Blood and lymphatic system Anaemia Common disorders Differential
Eintrag öffnenNezglyal · 4.8 · Table 4: Adverse reactions
Eintrag öffnenNezglyal · 4.8 · The overall safety profile of leriglitazone is based on clinical studies and additional clinical experience in
Eintrag öffnenNezglyal · 4.8 · The safety of leriglitazone in paediatric patients with ALD was evaluated in an open label Phase II study MT-2
Eintrag öffnenNezglyal · 4.8 · There are no data available on the use of leriglitazone in patients under 2 years of age.
Eintrag öffnenNezglyal · 4.8 · Weight increase Weight increase has been reported in 8.7% in children (2 to 12 years of age). Most events were
Eintrag öffnen